Husain Maroof, Shukla Rakesh, Dikshit Madhu, Maheshwari Pradeep K, Nag Devika, Srimal Rikhab C, Seth Prahlad K, Khanna Vinay K
Developmental Toxicology Division, Indian Institute of Toxicology Research, (Formerly Industrial Toxicology Research Centre), MG Marg, P.O. Box 80, Lucknow 226001, India.
Neurochem Res. 2009 Aug;34(8):1427-32. doi: 10.1007/s11064-009-9929-4. Epub 2009 Mar 4.
A case-control study was undertaken to investigate the status of platelet monoamine oxidase-B (MAO-B) activity in Indian cases of idiopathic Parkinson's disease. A significant increase in the activity of platelet MAO-B was observed in Parkinson's cases (n = 26) as compared to controls (n = 26). No significant change in the activity of the enzyme was observed while the data was analysed with respect to age, sex and duration of disease. A trend of decrease in platelet MAO-B activity was observed in Parkinson's cases with respect to stage although the change was not significant. No correlation in platelet MAO-B activity was observed with respect to age and sex in the control subjects. Parkinson's cases treated with L-DOPA and MAO-B inhibitor exhibited decreased platelet MAO-B activity as compared to drug naive cases and those treated with L-DOPA alone. Interestingly, Parkinson's cases treated with L-DOPA and amantadine also had lower platelet MAO-B activity as compared to drug naive cases and those treated with L-DOPA alone. Activity of platelet MAO-B in Parkinson's patients was increased in naive cases and those treated with L-DOPA alone or in combination with other drugs compared to controls. The results of the present study indicate that phenotypic activity of platelet MAO-B is high in Indian Parkinson's cases. Further, action mechanism of drugs used in the treatment of Parkinson's disease could be understood by assay of platelet MAO-B activity. It is an interesting observation and may be looked further in large number of cases.
开展了一项病例对照研究,以调查印度特发性帕金森病患者血小板单胺氧化酶-B(MAO-B)的活性状况。与对照组(n = 26)相比,帕金森病患者(n = 26)的血小板MAO-B活性显著增加。在按年龄、性别和病程分析数据时,未观察到该酶活性有显著变化。尽管变化不显著,但在帕金森病患者中观察到血小板MAO-B活性随疾病分期有下降趋势。在对照组中,未观察到血小板MAO-B活性与年龄和性别之间存在相关性。与未用药的病例以及仅接受左旋多巴治疗的病例相比,接受左旋多巴和MAO-B抑制剂治疗的帕金森病病例血小板MAO-B活性降低。有趣的是,与未用药的病例以及仅接受左旋多巴治疗的病例相比,接受左旋多巴和金刚烷胺治疗的帕金森病病例血小板MAO-B活性也较低。与对照组相比,未用药的帕金森病患者以及仅接受左旋多巴治疗或与其他药物联合治疗的患者血小板MAO-B活性升高。本研究结果表明,印度帕金森病病例中血小板MAO-B的表型活性较高。此外,通过检测血小板MAO-B活性可以了解帕金森病治疗药物的作用机制。这是一个有趣的观察结果,可能需要在大量病例中进一步研究。